VRCA Q1 2025 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

VRCAVerrica Pharmaceuticals Inc.

$56M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-10.1% YoY

Gross Profit

$3M87.7% margin

Operating Income

-$8M-236.4% margin

Net Income

-$10M-283.3% margin

EPS (Diluted)

$-1.03

QoQ Revenue Growth

+899.7%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$42M

Total Liabilities

$61M

Stockholders' Equity

-$19M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-10.1%
Gross Profit	$3M	$3M	+12.2%
Operating Income	-$8M	-$19M	+56.3%
Net Income	-$10M	-$20M	+52.1%

Revenue Segments

Product

$3M100%

Collaboration

$17,0000%